159 related articles for article (PubMed ID: 33565118)
1. Patient preference elicitation instrument, OABCare, to facilitate shared decision-making in the care of overactive bladder.
Chhatre S; Newman DK; Wein AJ; Jayadevappa R
Neurourol Urodyn; 2021 Mar; 40(3):791-801. PubMed ID: 33565118
[TBL] [Abstract][Full Text] [Related]
2. Delivering patient-centered care through shared decision making in overactive bladder.
Paudel R; Lane GI
Neurourol Urodyn; 2022 Apr; 41(4):884-893. PubMed ID: 35332575
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
4. Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder.
Iyer S; Amegashie C; deMartelly V; Letko J; Glass D; Fetzer L; Botros S; Wroblewski K; Valaitis S
J Urol; 2021 Nov; 206(5):1240-1247. PubMed ID: 34184922
[TBL] [Abstract][Full Text] [Related]
5. Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.
Anger JT; Nissim HA; Le TX; Smith AL; Lee U; Sarkisian C; Litwin MS; Raz S; Rodriguez LV; Maliski SL
Neurourol Urodyn; 2011 Sep; 30(7):1295-9. PubMed ID: 21538495
[TBL] [Abstract][Full Text] [Related]
6. Knowledge and attitude for overactive bladder care among women: development and measurement.
Chhatre S; Newman DK; Wein AJ; Jefferson AE; Schwartz JS; Jayadevappa R
BMC Urol; 2018 Jun; 18(1):56. PubMed ID: 29866095
[TBL] [Abstract][Full Text] [Related]
7. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
[TBL] [Abstract][Full Text] [Related]
9. Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder.
Beusterien K; Kennelly MJ; Bridges JF; Amos K; Williams MJ; Vasavada S
Neurourol Urodyn; 2016 Nov; 35(8):1028-1033. PubMed ID: 26370222
[TBL] [Abstract][Full Text] [Related]
10. A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?
Chapple CR; Kelleher CJ; Evans CJ; Kopp Z; Siddiqui E; Johnson N; Mako M
Eur Urol; 2016 Nov; 70(5):799-805. PubMed ID: 27160948
[TBL] [Abstract][Full Text] [Related]
11. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US.
Athavale A; Gooch K; Walker D; Suh M; Scaife J; Haber A; Hadker N; Dmochowski R
Patient Prefer Adherence; 2018; 12():2139-2152. PubMed ID: 30349208
[TBL] [Abstract][Full Text] [Related]
12. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW
J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937
[TBL] [Abstract][Full Text] [Related]
13. Determining patient preferences in the treatment of medication-refractory overactive bladder.
Speed J; Welk B; Comiter C; Elliott C
Neurourol Urodyn; 2023 Feb; 42(2):419-426. PubMed ID: 36480150
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
15. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
16. Communicating under medical patriarchy: gendered doctor-patient communication between female patients with overactive bladder and male urologists in Hong Kong.
Siu JY
BMC Womens Health; 2015 May; 15():44. PubMed ID: 26021313
[TBL] [Abstract][Full Text] [Related]
17. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).
Lee KS; Choo MS; Seo JT; Oh SJ; Kim HG; Ng K; Lee KJ; Tan JT; Kim JC
Health Qual Life Outcomes; 2015 Jun; 13():89. PubMed ID: 26113125
[TBL] [Abstract][Full Text] [Related]
18. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
19. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.
Johnston KM; Walker DR; Lakzadeh P
Adv Ther; 2019 Mar; 36(3):548-562. PubMed ID: 30715686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
